In 2009, the economy was on the floor. Banks were failing. Budgets were frozen. And somewhere in the middle of it, Dr. Roxie Mooney and two colleagues quietly started planning something that didn’t yet have a name, a website, or even a business card.
Just a clear point of view: Healthcare marketing was boring. And it needed to stop being boring.
That wasn’t just an opinion. It was a diagnosis. And like any good diagnosis, it came with a treatment plan. That treatment plan would soon become Legacy DNA.
Though the company was nameless at the time, the idea was already there. To build something that lasts; a legacy. To make it visible. To make it valuable. That thinking is still in our DNA.
In 2010, Legacy DNA was born with no office, no logo, no website, and no pitch deck. Just a founder with deep expertise in healthcare strategy and an obsession with innovation, a medical writer with years spent in health tech, pharma, and health systems, and a Fortune 100 graphic designer who knew that healthcare audiences deserved the same creative sophistication as any other sector. Maybe more.
Dynamite comes in small packages. And this particular package covered strategy, science, and story from day one.
The first two years ran entirely on word of mouth. No SEO. No ads. No LinkedIn campaigns. Just reputation, relationships, and results. In an industry that had spent decades recycling the same gray-scrubs-and-smiling-doctors playbook, the idea that healthcare marketing could be smarter, sharper, and grounded in science was apparently a refreshing thing to hear.
It spread.
The work that came in during those early years wasn’t small. The team was advising specialty pharmacies, working with early ACA organizations, and helping virtual health provider platforms find their footing in a market that wasn’t yet sure what to make of them. The clients were early movers. The problems were genuinely hard. And the approach, strategy built on behavioral science rather than just creative instinct, was something the industry hadn’t seen much of.
It wasn’t chaos exactly. But it wasn't cake yet either.
While the work was taking shape, so was the operating model. Legacy DNA was virtual from day one. Not pandemic-virtual, not reluctantly virtual, not “we’re-still-figuring-out-Zoom” virtual. Intentionally, structurally, philosophically virtual.
The tool of choice in those early days was GoToMeeting. If you weren’t in healthcare tech circles in 2009 and 2010, you may not fully appreciate what that meant. Video meetings were not the norm. Conference calls were. The idea of actually seeing your consultant’s face on a screen while sharing a presentation was, for many clients, a genuinely novel experience. There were frozen screens. There were muted microphones that nobody realized were muted. There were clients who called in on a landline because they didn’t trust the internet with something this important.
The team ran client engagements, strategy sessions, and creative reviews through all of it. Distributed by design. Built around outcomes, not office space. The model that the rest of the world would eventually be forced to adopt in 2020 was simply how Legacy DNA worked from the beginning.
Being early to virtual wasn’t a workaround. It was a feature.
The recession gets credit for a lot of company origin stories. But Legacy DNA wasn’t born out of desperation. It was born out of opportunity and frustration.
The frustration was real. Healthcare marketing, for all the complexity and stakes of the industry it served, was stuck. It looked the same year after year. The same messaging frameworks. The same visual language. The same assumption that healthcare audiences needed to be talked at rather than engaged. The founding team had spent enough time inside the industry to know that this wasn’t just aesthetically boring. It was strategically ineffective.
The opportunity was equally real. The ACA was coming. Health tech was accelerating. Virtual care was trying to find a language that patients and providers would actually respond to. The entire healthcare landscape was on the verge of a decade-long transformation, and the marketing infrastructure supporting it hadn’t evolved to meet the moment.
That gap, between where healthcare communication was and where it needed to be, was exactly where Legacy DNA planted its roots. Not as a campaign shop, but as a firm built to understand how healthcare companies actually grow and hold value.
Dr. Roxie built Legacy DNA on a simple conviction: healthcare marketing fails when it ignores how people actually make decisions. How clinicians evaluate evidence. How patients process risk. How executives weigh priorities under pressure.
As a commercialization strategist and board-level advisor whose career bridges doctoral-level research and hands-on execution in complex, regulated markets, she knew the difference between work that looked good and work that actually moved people.
That distinction became the foundation of everything Legacy DNA built.
“Stop being boring” was the rallying cry. The science underneath the story was what made it stick.
By the time Legacy DNA had a bonafide website and something resembling a formal business, it already had a track record. The word-of-mouth years weren’t just a scrappy origin story. They were a proof of concept.
By year two, the work had outgrown the founding team, in the best possible way. The client roster was expanding. The problems were getting more complex. And it was time to build.
Not all at once. It happened organically, the way good teams tend to build. One talented person at a time, each brought in because the work demanded it and the fit was right.
Strategists who had been close enough to the hard decisions to know what actually works. Writers who understood the clinical world as well as they understood good sentence structure. Digital technologists who knew that a healthcare website wasn’t just a design problem. It was a trust problem. And eventually, AI experts, because when the technology that Legacy DNA had been working alongside for years finally became the thing everyone was talking about, the firm already had people who understood it.
The team grew exponentially. The founding philosophy didn’t change at all.
There’s an unexpected truth to doing good work for a long time in a single industry: eventually, the work evolves whether you plan it or not.
What started as a healthcare marketing firm became something harder to categorize and more valuable to the clients who needed it. Because the healthcare companies Legacy DNA worked with weren’t just asking for better campaigns. They were asking bigger questions.
How do we build a business that a buyer will understand? How do we make sure the value we’ve created is visible, defensible, and transferable? How do we tell a healthcare growth story that holds up under scrutiny?
Those weren’t marketing questions. They were commercialization questions. Answering them well meant going inside the business, finding the commercial structure that explained why it works, and making it visible. Not just a compelling story. A credible one. Scalable. Transferable. One that held up when a buyer looked hard at it.
The work was straightforward, even when the problems weren’t. The rallying cry evolved: Help healthcare companies grow; make that growth visible and defensible; get them ready for what comes next.
Dr. Roxie and the team measured success simply. Did the people who built it get rewarded? Did the innovation continue? Did the impact outlast the transaction? If the answer was yes, the work was done right.
Most founding stories have a dramatic moment. This one had word of mouth, a recession, and a point of view strong enough to make up for the lack of everything else.
There was no single lightning bolt moment. No famous garage. No famous first check. There was just the work done well, for the right clients, at the right time. And the quiet confidence of a team that knew the industry needed exactly what they were building, even if the industry didn't know it yet.
They were right. And they built accordingly.
Sixteen years later, the healthcare landscape looks almost nothing like it did in 2010. The ACA reshaped coverage. Specialty pharmacy redefined drug spend. COVID-19 detonated the old assumptions about how care gets delivered. AI went from science fiction to strategic imperative.
Legacy DNA was present for every single one of those shifts. Not as a bystander. As a builder.
The chaos was real. The cake was worth it. And what we’ve learned over sixteen years is something we really knew all along: growth alone isn’t the goal. Building something that lasts is.
That’s the work. That’s the standard. And that’s the legacy we’re still building.
Healthcare marketing spent decades operating on assumptions that don't hold up under scrutiny — that clinical audiences respond to authority rather than evidence, that patients need information rather than engagement, and that creativity was a luxury the industry couldn't afford. The result was a sector that recycled the same messaging frameworks and visual language year after year, not because they worked, but because no one had pressure-tested whether they did.
It produces work that looks reasonable but doesn't move people. Clinicians don't evaluate information the way a general consumer does. Patients process risk differently depending on how choices are framed. Executives make decisions under constraints that change the weight of any given message. Marketing that ignores these distinctions tends to inform without influencing — which in healthcare, where behavior change is often the actual goal, is a significant failure.
Most healthcare companies build value incrementally — through relationships, clinical outcomes, operational decisions, and institutional knowledge — without ever constructing a coherent external narrative around it. The value is real, but it lives inside the organization. When a buyer, partner, or investor looks at the business from the outside, what they see is revenue data and a pitch deck. The commercial structure that explains why the business works — and why it will keep working — is rarely visible until someone forces the question.
Yes, and it's a consequential one. A compelling story is easy to construct — it emphasizes momentum, frames challenges as opportunities, and leads with vision. A credible story holds up when someone looks hard at it: when the assumptions are stress-tested, when the revenue drivers are traced to their source, when the question of whether the value transfers without the founder gets a real answer. In M&A, due diligence is specifically designed to close the gap between the two.
The ACA didn't just expand coverage — it accelerated the entry of new organizational types into the healthcare market, many of which had no established commercial playbook. Early ACO structures, co-ops, value-based care arrangements, and expanded specialty pharmacy channels all emerged in a short window, each needing to build market positioning, stakeholder communication strategies, and growth infrastructure largely from scratch, often simultaneously.
The technology existed well before adoption followed. The barrier wasn't capability — it was language. Virtual care platforms in the early 2010s were trying to communicate a fundamentally different care model to patients accustomed to in-person visits and providers trained in physical examination. The value proposition was real, but the messaging frameworks being used were borrowed from existing healthcare communication norms that weren't built for a digital-first relationship between provider and patient.
Exit-readiness is less about financial performance than most founders assume. A buyer needs to understand not just what a business earns, but why — and whether that will remain true after the transaction closes. That means the value drivers need to be documented, the commercial logic needs to be visible, and the growth story needs to be defensible under the kind of scrutiny that due diligence applies. Companies that haven't built that structure before a buyer appears are typically building it under pressure, which produces a weaker result.
